专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07074589B1 Nucleic acids encoding BDP-1 失效
标题翻译：编码BDP-1的核酸
公开(公告)号：US07074589B1
公开(公告)日：2006-07-11
申请号：US08877150
申请日：1997-06-17
申请人： Axel Ullrich , Naohito Aoki , Yeong Woong Kim , Hong Yang Wang , Zhengjun Chen , Oliver Nayler , Alexei Kharitonenkov
发明人： Axel Ullrich , Naohito Aoki , Yeong Woong Kim , Hong Yang Wang , Zhengjun Chen , Oliver Nayler , Alexei Kharitonenkov
IPC分类号： C12P21/06
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4703 , C07K16/18 , C07K16/40 , C12N9/16
摘要： Nucleic acid molecules encoding full length PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptides, portions of such nucleic acid molecules, nucleic acid vectors containing such nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind such polypeptides or abrogate their interactions with natural binding partners. Methods for diagnosing abnormal conditions in an organism with PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP related molecules or compounds. PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, or SIRP polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for diseases related to PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptide or conditions characterized by an abnormal interaction between such a polypeptide and its binding partner.
摘要翻译：编码全长PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4和SIRP多肽的核酸分子，这些核酸分子的部分，含有该核酸分子的核酸载体，含有该核酸载体的重组细胞，纯化的多肽来自这样的重组细胞，对这些多肽的抗体，以及鉴定结合这些多肽的化合物或废除其与天然结合配偶体的相互作用的方法。用于诊断具有PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4和SIRP相关分子或化合物的生物体的异常状况的方法。 PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4或SIRP多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，使用此类多肽的抗体，以及与所有这些多肽相关的方法以上。提供了与PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4和SIRP多肽有关的疾病或特征为这种多肽与其结合配偶体之间异常相互作用的病症的治疗，诊断和筛选方法。

2. 发明授权

US6004791A Protein tyrosine phosphatase PTP20 and related products and methods 失效
公开(公告)号：US6004791A
公开(公告)日：1999-12-21
申请号：US951260
申请日：1997-10-16
申请人： Naohito Aoki , Axel Ullrich
发明人： Naohito Aoki , Axel Ullrich
IPC分类号： A61K38/00 , C07K14/47 , C07K16/18 , C07K16/40 , C12N9/12 , C12N9/16 , C07H21/04 , C12N1/20
CPC分类号： C12N9/1205 , C07K14/4703 , C07K16/18 , C07K16/40 , C12N9/16 , A61K38/00
摘要： The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide. The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.

3. 发明申请

US20080051556A1 Novel PTP-20, PCP-2, BDP1, CLK, and SIRP proteins and related products and methods 审中-公开
标题翻译：新型PTP-20，PCP-2，BDP1，CLK和SIRP蛋白及相关产品及方法
公开(公告)号：US20080051556A1
公开(公告)日：2008-02-28
申请号：US11153918
申请日：2005-06-16
申请人： Axel Ullrich , Naohito Aoki , Yeong Woong Kim , Hong Yang Wang , Zhengjun Chen , Oliver Nayler , Alexei Kharitonenkov
发明人： Axel Ullrich , Naohito Aoki , Yeong Woong Kim , Hong Yang Wang , Zhengjun Chen , Oliver Nayler , Alexei Kharitonenkov
IPC分类号： C07K2/00 , C07H21/00 , C07K16/00
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4703 , C07K16/18 , C07K16/40 , C12N9/16
摘要： Nucleic acid molecules encoding full length PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptides, portions of such nucleic acid molecules, nucleic acid vectors containing such nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind such polypeptides or abrogate their interactions with natural binding partners. Methods for diagnosing abnormal conditions in an organism with PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP related molecules or compounds. PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, or SIRP polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for diseases related to PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptides or conditions characterized by an abnormal interaction between such a polypeptide and its binding partner.
摘要翻译：编码全长PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4和SIRP多肽的核酸分子，这些核酸分子的部分，含有该核酸分子的核酸载体，含有该核酸载体的重组细胞，纯化的多肽来自这样的重组细胞，对这些多肽的抗体，以及鉴定结合这些多肽的化合物或废除其与天然结合配偶体的相互作用的方法。用于诊断具有PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4和SIRP相关分子或化合物的生物体的异常状况的方法。 PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4或SIRP多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，使用此类多肽的抗体，以及与所有这些多肽相关的方法以上。为与PTP20，PCP-2，BDP1，mCLK2，mCLK3，mCLK4和SIRP多肽相关的疾病或特征为这种多肽与其结合配偶体之间的异常相互作用的病症提供了治疗，诊断和筛选方法。

4. 发明授权

US06482605B1 Protein tyrosine phosphatase PTP20 and related products and methods 失效
标题翻译：蛋白酪氨酸磷酸酶PTP20及相关产品及方法
公开(公告)号：US06482605B1
公开(公告)日：2002-11-19
申请号：US09430626
申请日：1999-10-29
申请人： Naohito Aoki , Axel Ullrich
发明人： Naohito Aoki , Axel Ullrich
IPC分类号： C12Q142
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4703 , C07K16/18 , C07K16/40 , C12N9/16
摘要： The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide . The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.
摘要翻译：本发明涉及新型多肽PTP20，以及编码该多肽的核酸分子。本发明还涉及编码部分磷酸酶的核酸分子，含有PTP20相关核酸分子的核酸载体，含有此类核酸载体的重组细胞，从这些重组细胞纯化的多肽，对这些多肽的抗体，以及鉴定化合物的方法结合PTP20或废除其与天然结合配偶体的相互作用。还公开了用PTP20相关分子或化合物诊断生物体中的异常状况的方法。

5. 发明授权

US08591903B2 Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation 失效
公开(公告)号：US08591903B2
公开(公告)日：2013-11-26
申请号：US12400122
申请日：2009-03-09
申请人： Axel Ullrich , Andreas Gschwind , Stefan Hart
发明人： Axel Ullrich , Andreas Gschwind , Stefan Hart
IPC分类号： A61K39/00 , A61K39/395 , A61K49/00
CPC分类号： C12N9/6489 , A61K38/005 , C07K14/485
摘要： The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an organism comprising inhibiting the activity of the metalloprotease TACE/ADAM17 and/or the activity of the receptor tyrosine kinase ligand amphiregulin.

6. 发明申请

US20120277231A1 QUINOLINYLOXYPHENYLSULFONAMIDES 有权
标题翻译：喹啉啉氧基硅烷
公开(公告)号：US20120277231A1
公开(公告)日：2012-11-01
申请号：US13500761
申请日：2010-10-16
申请人： Axel Ullrich , Robert Torku , Yixiang Zhang , György Kéri , László Örfi , István Szabadkai
发明人： Axel Ullrich , Robert Torku , Yixiang Zhang , György Kéri , László Örfi , István Szabadkai
IPC分类号： A61K31/47 , A61K31/4709 , A61P35/00 , A61K31/496 , C07D405/12 , C07D401/14 , C07D413/12 , A61K31/5375 , C07D215/233 , C07D401/12 , C07D409/14
CPC分类号： C07D417/12 , C07D215/20 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12
摘要： The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.
摘要翻译：本发明涉及这些喹啉氧基苯基磺酰胺化合物的喹啉氧基苯磺酰胺和立体异构形式，溶剂合物，水合物和/或药学上可接受的盐，以及含有至少一种这些化合物以及至少一种药学上可接受的载体，赋形剂和/或稀释剂的药物组合物。所述喹啉氧基苯基磺酰胺可用于预防，治疗和/或治疗过度增殖性疾病，如癌症，肿瘤，特别是癌症转移。

7. 发明授权

US08277802B2 Diagnosis and prevention of cancer cell invasion 有权
标题翻译：诊断和预防癌细胞侵袭
公开(公告)号：US08277802B2
公开(公告)日：2012-10-02
申请号：US10521410
申请日：2003-07-17
申请人： Axel Ullrich , Pjotr Knyazev , Tatjana Knyazeva , Yuri Cheburkin , Peter Vajkoczy
发明人： Axel Ullrich , Pjotr Knyazev , Tatjana Knyazeva , Yuri Cheburkin , Peter Vajkoczy
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： A61K39/3955 , A61K2039/505 , C07K16/2863 , C12Q1/6886 , C12Q2600/136
摘要： The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. Most particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.
摘要翻译：本发明涉及恶性疾病领域的诊断和治疗方法。最特别地，本发明提供了确定恶性疾病的侵袭性的方法和降低恶性疾病的侵袭性的方法，包括预防或治疗癌细胞侵袭。

8. 发明申请

US20110179505A1 RODENT CANCER MODEL FOR HUMAN FGFR4 ARG388 POLYMORPHISM 审中-公开
标题翻译：人类FGFR4 ARG388多态性模型
公开(公告)号：US20110179505A1
公开(公告)日：2011-07-21
申请号：US13121202
申请日：2009-09-29
申请人： Axel Ullrich , Thomas Mayer , Sylvia Streit , Nina Seitzer
发明人： Axel Ullrich , Thomas Mayer , Sylvia Streit , Nina Seitzer
IPC分类号： A01K67/00 , A01K67/027 , C12N5/10 , A61K38/22 , C07H21/00 , C12N15/85 , G01N33/574 , C07H21/02 , C07K16/18
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/072 , A01K2227/105 , A01K2267/0331 , C07K14/71
摘要： The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e.g. cancer, and with a modified FGFR4.
摘要翻译：本发明提供了一种啮齿动物，用于研究与不受控制的细胞生长相关的分子机制和生理过程，例如，癌症和改良的FGFR4。

9. 发明申请

US20100184686A1 USE OF INHIBITORS FOR THE TREATMENT OF RTK-HYPERFUNCTION-INDUCED DISORDERS, PARTICULARLY CANCER 有权
标题翻译：使用抑制剂治疗RTK超敏感性疾病，特别是癌症
公开(公告)号：US20100184686A1
公开(公告)日：2010-07-22
申请号：US12689672
申请日：2010-01-19
申请人： Axel Ullrich , Johannes Bange , Pjotr Knyazev
发明人： Axel Ullrich , Johannes Bange , Pjotr Knyazev
IPC分类号： A61K38/17 , C07K14/71 , C07H21/04 , C07K16/28 , A61P35/04 , A61P35/00 , C12Q1/68 , C12Q1/48
CPC分类号： C07K14/71 , A61K38/00 , G01N33/574
摘要： The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to over-expression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule. Finally, in addition the invention concerns a pharmaceutical composition, containing the inhibitor as described above and further a diagnostic and screening procedure.
摘要翻译：本发明涉及抑制剂用于治疗和/或预防由于受体酪氨酸激酶活性增加，特别是癌症引起的疾病的用途。该用途特别涉及抑制或降低受体酪氨酸激酶（RTK）的过表达和/或改变的活性。特别地，受体酪氨酸激酶的这种改变的活性可以由FGFR-4的突变引发，其中该突变特别是FGFR-4的跨膜结构域中的点突变，并导致疏水性氨基酸的交换亲水氨基酸。本发明还涉及使用针对FGFR-4的抑制剂来治疗和/或预防癌症。此外，本发明涉及突变的FGFR-4，其导致细胞中过度表达和/或改变的活性。最后，本发明涉及突变的FGFR-4分子的DNA和RNA序列。最后，本发明还涉及包含如上所述的抑制剂的药物组合物，并进一步进行诊断和筛选程序。

10. 发明授权

US07297774B2 Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer 有权
标题翻译：使用抑制剂治疗RTK-超功能障碍，特别是癌症
公开(公告)号：US07297774B2
公开(公告)日：2007-11-20
申请号：US10863880
申请日：2004-06-08
申请人： Axel Ullrich , Johannes Bange , Pjotr Knyazev
发明人： Axel Ullrich , Johannes Bange , Pjotr Knyazev
IPC分类号： C07K14/00 , C12N15/11 , C12P21/06
CPC分类号： C07K14/71 , A61K38/00 , G01N33/574
摘要： The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule. Finally, in addition the invention concerns a pharmaceutical composition, containing the inhibitor as described above and further a diagnostic and screening procedure.
摘要翻译：本发明涉及抑制剂用于治疗和/或预防由于受体酪氨酸激酶活性增加，特别是癌症引起的疾病的用途。该用途特别涉及抑制或降低受体酪氨酸激酶（RTK）的过表达和/或改变的活性。特别地，受体酪氨酸激酶的这种改变的活性可以由FGFR-4的突变引发，其中该突变特别是FGFR-4的跨膜结构域中的点突变，并导致疏水性氨基酸的交换亲水氨基酸。本发明还涉及使用针对FGFR-4的抑制剂来治疗和/或预防癌症。此外，本发明涉及突变的FGFR-4，其导致细胞中的过表达和/或改变的活性。最后，本发明涉及突变的FGFR-4分子的DNA和RNA序列。最后，本发明还涉及包含如上所述的抑制剂的药物组合物，并进一步进行诊断和筛选程序。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式